

Picking the best isoform

Citation for published version (APA):

Paes, D. (2023). Picking the best isoform: PDE4D isoforms as therapeutic targets in Alzheimer's disease. [Doctoral Thesis, Maastricht University, Hasselt University/tUL]. Maastricht University. https://doi.org/10.26481/dis.20231117dp

Document status and date: Published: 01/01/2023

DOI: 10.26481/dis.20231117dp

Document Version: Publisher's PDF, also known as Version of record

Please check the document version of this publication:

 A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.

• The final author version and the galley proof are versions of the publication after peer review.

 The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these riahts.

· Users may download and print one copy of any publication from the public portal for the purpose of private study or research.

- You may not further distribute the material or use it for any profit-making activity or commercial gain
 You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

STATEMENTS

Picking the best isoform

PDE4D isoforms as therapeutic targets in Alzheimer's disease

Dean Paes

- 1. If a gene encodes multiple protein isoforms, it very likely does so for a good reason.
- 2. Targeting specific rather than all PDE4D isoforms will be therapeutically superior in treating memory problems associated with Alzheimer's disease.
- 3. Synergistic actions of PDE4 and PDE2 inhibition should be explored as an effective and safe treatment strategy for treating memory deficits in Alzheimer's disease.
- 4. Measuring the affinity of a PDE4 inhibitor is highly dependent on the sequence and the conformational state of the PDE4 construct used, of which the latter is dependent on the type of assay used.
- 5. Drug development efforts should focus on the target in its native state(s) rather than screening compounds in cell-free assays using truncated target constructs.
- 6. Cell culture experiments should be complemented with computational biology approaches to reveal some of the complex non-linear dynamics in the otherwise 'black box'.
- 7. The best interventions for Alzheimer's disease may be those applied before its onset.
- 8. Target specification to the level of protein isoforms can improve therapeutic efficacy and, therefore, should be explored for any pharmacological target for any disease.
- 9. Life is nothing but an electron looking for a place to rest.
 Albert Szent-Györgyi
- 10. Knowledge isn't free. You have to pay attention. - Richard Feynman
- βούλεσθαι μάλλον μίαν εύρειν αἰτιολογίαν ἢ τὴν Περσῶν οἱ βασιλείαν γενέσθαι (I would rather discover one true cause than gain the kingdom of Persia.)
 - Democritus